Switch View
© BusinessWire
22.09.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
News Preview
Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portf...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF WESLEY BAMBURG AS ITS NEW CHIEF OPERATING OFFICER
News Preview
HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today announced the appoint...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CH0334081137
CRISPR Therapeutics AG
CRSP
LISTED
NASDAQ
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
News Preview
ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company developing innovative small...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
22.09.2025
ISIN: US0044685008
Achieve Life Sciences, Inc.
ACHV
LISTED
NASDAQ
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD
News Preview
New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
22.09.2025
ISIN: US4579852082
Integra Lifesciences Holdings Corp
IART
LISTED
NASDAQ
Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
News Preview
Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CA64119M1059
Netramark Holdings Inc
AIAI
LISTED
CSE
NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
News Preview
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a new collaboration focused on gliobl...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US74051N1028
Premier Inc
PINC
LISTED
NASDAQ
Premier, Inc. Announces Definitive Agreement to Be Acquired by Patient Square Capital in Transaction Valued at $2.6 Billion
News Preview
Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-driven health care improvement company, today announced that it has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital (“Patient Square”).
Under the terms of the agreement, which has been unanimously approved by Premier’s Boa...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CA48213Y1079
Jushi Holdings Inc.
JUSH
LISTED
CSE
Jushi Holdings Inc. Announces Favorable Modifications to Existing Manassas, VA Mortgage
News Preview
Company received $4,000,000 of additional loan proceeds...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US0017441017
AMN Healthcare Services Inc
AMN
LISTED
NYSE
AMN Healthcare Launches $400.0 Million Offering of Senior Notes
News Preview
DALLAS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), announced today that its wholly owned subsidiary, AMN Healthcare, Inc., intends to make a private offering of $400.0 million aggregate principal amount of senior unsecured notes due 2031, subject to market and other conditions. The 2031 Notes will be guaranteed...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US21833P3010
Corbus Pharmaceuticals Holdings Inc
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
News Preview
KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701 KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US2214133058
Cosmos Health Inc
COSM
LISTED
NASDAQ
Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue
News Preview
Cosmos Health commences U.S. operations with its Sky Premium Life brand, supported by local manufacturing capabilities. Anticipates strong cash flow....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US15678C1027
Ceribell, Inc.
CBLL
LISTED
NASDAQ
Medtech Leader Erica Rogers Joins Ceribell Board of Directors
News Preview
Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
22.09.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
News Preview
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR”) (NASDAQ:STAA), today announced its opposition to the Company’s proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025.
Yunqi Capital re...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: DE000BAY0017
Bayer AG
BAYN
LISTED
XETR
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
News Preview
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for PD. At the same time, first European participants have been randomized in REGENERATE-PD, a Phase II...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: AU000000SPL0
Starpharma Holdings Ltd
SPL
LISTED
ASX
Starpharma Announces a Collaboration and License Agreement with Genentech
News Preview
MELBOURNE, Australia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, US OTC: SPHRY), an innovative Australian biotechnology company, today announced the signing of a collaboration and license agreement with Genentech, a member of the Roche Group, to develop potential cancer therapies that leverage Starpharma’s proprietary DEP® drug deli...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US45826J1051
Intellia Therapeutics Inc
NTLA
LISTED
NASDAQ
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
News Preview
Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of patient follow-up and additional insight into ATTRv-PN disease-relevant measures Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
News Preview
PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clinical trials oral presentation, one oral presentation, and three poster sessions will be shared at the Heart Fail...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US98419J2069
XOMA Royalty Corp
XOMA
LISTED
NASDAQ
XOMA Royalty Declares Quarterly Preferred Stock Dividends
News Preview
XOMA Royalty announces October 2025 dividend...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US55287L1017
MBX Biosciences, Inc.
MBX
LISTED
NASDAQ
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
News Preview
Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE)...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
News Preview
REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending appro...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
News Preview
REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion rec...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.09.2025
ISIN: US45408X3089
IGC Pharma, Inc
IGC
LISTED
XASE
IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
News Preview
POTOMAC, MD / ACCESS Newswire / September 22, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has reached a key enrollment milestone of 50% for its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer'...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.09.2025
ISIN: US5845073056
Medical Care Technologies Inc.
MDCE
LISTED
OTC
Medical Care Technologies Inc. Introduces AI Breakthrough for Squamous Cell Carcinoma Detection
News Preview
MESA, ARIZONA / ACCESS Newswire / September 22, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a significant innovation in dermatological AI: a platform capable of detecting squamous cell carcinoma (SCC), the second most common skin cancer and a condition responsible for more than 15,000 deaths annually in the United States a...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
News Preview
REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital,...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
News Preview
REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty,...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US89377M1099
Transmedics Group Inc
TMDX
LISTED
NASDAQ
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
News Preview
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need
TransMedics President and Chief Executive Officer, Waleed Hassanein, M.D., to discu...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US89377M1099
Transmedics Group Inc
TMDX
LISTED
NASDAQ
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
News Preview
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need
TransMedics President and Chief Executive Officer, Waleed Hassanein, M.D., to discu...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.09.2025
ISIN: US60458C1045
Mira Pharmaceuticals Inc
MIRA
LISTED
NASDAQ
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
News Preview
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The drug showed rapid and predictable absorption, a favorable duration of action supporting once-daily dosing, and no CNS side effects typically seen with k...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.09.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech to be included in the SPI ESG Index
News Preview
Media release as at September 22, 2025
BB Biotech to be included in the SPI ESG Index
BB Biotech AG announces that it will be included in the SPI ESG Index of the SIX Swiss Exchange as of today, September 22, 2025. This highlights the investment company’s long-standing commitment to responsible investing and sustainable corporate governance.
Dr.......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.09.2025
ISIN: CH1110760852
PolyPeptide Group AG
PPGN
LISTED
SIX
PolyPeptide Group achieves significant milestone in Malmö expansion project
News Preview
PolyPeptide Group
/ Key word(s): Expansion
PolyPeptide Group achieves significant milestone in Malmö expansion project
22.09.2025 / 07:00 CET/CEST
Media Release
PolyPeptide Group achieves significant milestone in Malmö expansion project
Baar, 22 September 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized, globa......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.09.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech wird in den SPI ESG Index aufgenommen
News Preview
Medienmitteilung vom 22. September 2025
BB Biotech wird in den SPI ESG Index aufgenommen
Die BB Biotech AG gibt bekannt, dass sie per heute, 22. September 2025 in den SPI ESG Index der SIX Swiss Exchange aufgenommen wird. Damit wird das langjährige Engagement der Investmentgesellschaft für verantwortungsbewusstes Investieren und nachhaltige Unter......
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
News Preview
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
News Preview
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
News Preview
PARIS, FRANCE, 22 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. Patients treated with IPN10200 showed a statistically significant improvement in response at Week 4 vs plac...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CH0363463438
Idorsia Ltd
IDIA
LISTED
SIX
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
News Preview
Allschwil, Switzerland – September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ® (daridorexant) in China. QUVIVIQ, Idorsia’s dual orexin receptor antagonist, is indicated for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
News Preview
Basel, 22 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA study evaluating investigational giredestrant in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer p...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
News Preview
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
News Preview
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: CNE100003F19
Wuxi Apptec Co., Ltd.
2359
LISTED
HKSE
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
News Preview
SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash...
Themefolio
Profiler
Peergroup
© BusinessWire
21.09.2025
ISIN: US8753722037
Tandem Diabetes Care Inc
TNDM
LISTED
NASDAQ
TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. (“Tandem” or “the Company”) (NASDAQ: TNDM) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or fail...
Themefolio
Profiler
Peergroup
© BusinessWire
21.09.2025
ISIN: US4718712023
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Themefolio
Profiler
Peergroup
© PR Newswire
21.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 21, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates i...
Themefolio
Profiler
Peergroup
© PR Newswire
21.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Sept. 21, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the "Cla...
Themefolio
Profiler
Peergroup
© PR Newswire
21.09.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 21, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.09.2025
ISIN: IL0006290147
Teva Pharmaceutical Industries Ltd
TEVA
LISTED
TLV
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUSTEDO XR rep...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.09.2025
ISIN: IL0006290147
Teva Pharmaceutical Industries Ltd
TEVA
LISTED
TLV
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
News Preview
PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of 10 posters from its innovative schizophrenia medicines portfolio, including long-term safety data from the completed SOLARIS Phase 3 tri...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2025
ISIN: US4718712023
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR), between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”). Jasper is a clinical-stage biotechnology company.
For more information...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL
News Preview
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
So what: If yo...
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman
News Preview
REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline
SAN FRANCISCO, Sept. 20, 2025 On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2025
ISIN: CA68237C1059
Onco-Innovations Limited
ONCO
LISTED
CSE
Steht die Aktie vor einer Neubewertung? Nanopartikel-Meilenstein ebnet Weg zu präklinischen Studien
News Preview
EQS-Media / 20.09.2025 / 15:40 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass “Dalton Pharma Services” (“Dalton”) seine Aktivitäten zur Herstellung der proprietären Nanopartikelformulierung von Onco, auch als “PEO-b-PBz-CL” Poly(ethylenoxid)-Block-Poly(-benzylcarb......
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
RXST Deadline: RXST Investors with Losses in Excess of $100K Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 20, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between May 7, 2024 and July 8, 2025, both dates inclusive (the "Clas...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2025
ISIN: US12529R1077
C4 Therapeutics Inc
CCCC
LISTED
NASDAQ
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
News Preview
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2025
ISIN: CA68237C1059
Onco-Innovations Limited
ONCO
LISTED
CSE
Onco-Innovations beginnt gemeinsam mit “Dalton Pharma” mit der Herstellung von Nanopartikelformulierungen für präklinische Tierstudien
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass “Dalton Pharma Services” (“Dalton”) seine Aktivitäten zur Herstellung der proprietären Nanopartikelformulierung von Onco, auch als “PEO-b-PBz-CL” Poly(ethylenoxid)-Block-Poly(-benzylcarboxylat -caprolacton) bezeichnet, begonnen hat......
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Did you lose money in LNTH? Shareholders Who Incurred Significant Losses in Lantheus Holdings, Inc. Should Contact Robbins LLP for Information
News Preview
SAN DIEGO, Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Lantheus Holdings, Inc. (NASAQ: LNTH) securities between February 26, 2025 and August 5, 2025. Lantheus is a global company that develops, manufactures, sells, and distribu...
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit
News Preview
SAN DIEGO, Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience, Inc. (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering ("IPO") conduc...
Themefolio
Profiler
Peergroup
© Newsfile
20.09.2025
ISIN: CA74141E1043
PreveCeutical Medical Inc.
PREV
LISTED
CSE
PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its News Release of September 4, 2025, it has filed with the applicable Canadian securities regulatory authorities the management information ci...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidas...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
News Preview
TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease
TREMFYA® achieved significant rates of clinical remission and endoscopic improvement versus placebo at Week 12 with a subcutaneous induction regimen, consistent with IV induction
Johnson...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US1266501006
CVS Health Corp
CVS
LISTED
NYSE
CVS Pharmacy celebrates reopening of Pacific Palisades store damaged by devastating wildfires
News Preview
The Swarthmore Avenue CVS Pharmacy is the first community pharmacy to reopen in the neighborhood, increasing access to health and wellness essentials
WOONSOCKET, R.I., Sept. 19, 2025 /PRNewswire/ -- Today, leaders from CVS Health® (NYSE: CVS) were joined by state and local representatives to celebrate the recently reopened Pacific Palisades CVS P...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: CA98421R1055
XPhyto Therapeutics Corp.
XPHY
LISTED
CSE
BioNxt Solutions Announces Closing of Shares for Debt Settlement
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of September 12, 2025, it has closed its debt settlement with an arm's length creditor (the "Creditor") related to an aggrega...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
